John Friend, MD, CEO of Kazia Therapeutics added, "The novelty of the science that Professor Rao has proposed with this dual ...
The 12-month open-label extension of the PACIFIC trial demonstrated that bexicaserin significantly reduced seizure frequency ...
In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation, discusses how MMRF ...
Recent survey study of 978 cancer patients and their relatives uncovered reasons behind their willingness, or lack thereof, ...
The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial ...
In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation, talks unmet need in ...
The promise of modern clinical trials is often hindered by a hidden burden: technology that fails to address the realities of clinical research. While science advances with breakthrough therapies and ...
Research from the Tufts Center for the Study of Drug Development’s PACT Consortium shows DCTs encourage higher participation ...
In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation, highlights the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback